NCT03737370 2025-10-07
Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer
Tufts Medical Center
Phase 1 Completed
Clinical Trials
29 trialsNCT03093428 2025-03-28
Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02043678 2025-02-19
ERA 223
Bayer
Phase 3 Completed
NCT03002220 2024-12-11
EXCAAPE
MedSIR
Phase 2 Completed
NCT03315260 2024-02-08
Treatment Satisfaction With Ra-223 in Japan
Bayer
Completed
NCT02903160 2024-02-07
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT04256993 2024-01-16
PRECISE
Bayer
Completed
NCT00337155 2023-11-02
BAY88-8223, Dose Finding Study in Patients With HRPC
Bayer
Phase 2 Completed
NCT04681144 2023-10-26
QOLRAD
Bayer
Completed
NCT02346526 2022-09-29
A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT04281147 2022-06-23
REACTIVATE
Bayer
Completed
NCT02135484 2022-02-17
Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases
M.D. Anderson Cancer Center
Phase NA Completed
NCT03062254 2021-09-21
Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy
Sir Mortimer B. Davis - Jewish General Hospital
Phase 2 Completed
NCT02463799 2021-07-08
Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02199197 2020-10-30
Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer
University of Utah
Phase 2 Completed
NCT03419442 2020-10-22
Multi-academic Center Study of Xofigo Patients
Bayer
Completed
NCT02034552 2019-07-23
A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)
Bayer
Phase 2 Completed
NCT02023697 2019-07-12
Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone
Bayer
Phase 2 Completed
NCT01810770 2018-09-19
Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis
Bayer
Phase 3 Completed
NCT02518698 2018-09-18
Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population
Bayer
Completed
NCT01929655 2018-04-24
Japanese BAY88-8223 Monotherapy Phase II Study
Bayer
Phase 2 Completed
NCT01934790 2018-03-26
Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases
Bayer
Phase 1/2 Completed
NCT02097303 2018-02-01
eRADicAte
Carolina Research Professionals, LLC
Phase 2 Completed
NCT02729103 2018-01-25
Treatment Patterns in Metastatic Prostate Cancer
Bayer
Completed
NCT01618370 2017-03-31
Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
Bayer
Phase 3 Completed
NCT01565746 2016-10-17
Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients
Bayer
Phase 1 Completed
NCT00667537 2015-12-14
PK in Pts With HRPC & Skeletal Metastes
Bayer
Phase 1 Completed
NCT00459654 2014-06-25
A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer
Bayer
Phase 2 Completed
NCT00748046 2014-06-25
Alpharadinâ„¢ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton
Bayer
Phase 1 Completed